ScripLong non-coding RNA (lncRNA) is an emerging therapeutic modality that may offer actionable novel targets in a variety of disease settings, and Eli Lilly and Company , already a leader in obesity and
ScripBayer is still in the midst of a radical overhaul of its business but has returned to in-licensing oncology assets via a deal with NextRNA Therapeutics and its novel small molecule platform. Findin
ScripAtlas Venture added more fuel to its biotechnology start-up engine with a $450m fund announced on 3 March, which the venture capital firm will invest in new companies developing novel therapeutics and